Delivery Order SPE2DR25D3014-SPE2DR26FP1FA
- Not listed
- The Defense Logistics Agency awarded a $53,478.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside competitive award is being performed at the company's corporate office in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a monoclonal antibody used to treat high cholesterol in patients with cardiovascular disease, and the SureClick...
- The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $18,738.83 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The place of performance is the company's corporate headquarters in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management, and the SureClick auto-injector delivery mechanism...
- The Defense Logistics Agency awarded a delivery order valued at $81,340.66 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on December 4, 2025, with completion expected by December 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $30,876.03 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick autoinjector pens on November 13, 2025, with an ultimate completion date of November 14, 2025. This competitive award utilizes firm fixed pricing and represents a single delivery transaction under a larger contract vehicle. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patients. The place of...
- The Defense Logistics Agency (DLA) awarded a $24,925.53 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed-price, competitively awarded contract was placed with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-competitive, firm fixed-price delivery order was issued on August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular...
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order valued at $55,794.54 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on October 29, 2025, with completion scheduled for October 30, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1FADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,894.64 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 4, 2025. This non-competitive delivery order was issued under a firm fixed-price contract structure and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick delivery system represents a patient-friendly pre-filled auto-injection mechanism. This delivery order represents a routine procurement action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999.999 billion ceiling value through December 2026. AmerisourceBergen serves as a critical pharmaceutical prime vendor for the Defense Health Agency and military healthcare systems, supplying a comprehensive portfolio of brand-name and generic medications, specialty drugs, and medical supplies across multiple therapeutic domains. The company's status as a major pharmaceutical distributor and established federal contractor enables it to fulfill specialized medical procurement requirements efficiently through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 12/2/25 |